Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Ovarian Neoplasms 5Fallopian Tube Neoplasms 3Carcinoma, Ovarian Epithelial 3Uterine Cervical Neoplasms 1Recurrent Uterine Corpus Carcinoma 1Peritoneal Neoplasms 1Neoplasms 1

Interventions

Carboplatin 159Paclitaxel 153Bevacizumab 85Taxes 48Gemcitabine 48liposomal doxorubicin 47Topotecan 41Cisplatin 35pembrolizumab 33Cyclophosphamide 28olaparib 25Immunoglobulin G 24Disulfides 24Specimen Handling 21Drug Therapy 20Docetaxel 20niraparib 18Magnetic Resonance Spectroscopy 18Doxorubicin 17Biopsy 15mirvetuximab soravtansine 14Hyperthermic Intraperitoneal Chemotherapy 14rucaparib 13Nivolumab 12Cytoreduction Surgical Procedures 11Chemotherapy, Adjuvant 10Albumin-Bound Paclitaxel 10veliparib 9Platinum 9Neoadjuvant Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Gefitinib × Gynecologic × Clear all
NCT00317772 2022-02-07

Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer

M.D. Anderson Cancer Center

Phase 1/2 Completed
19 enrolled 12 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT00049556 2013-06-20

Gefitinib in Treating Patients With Cervical Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Gynecologic

Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00189358 2010-07-20

A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy

AGO Study Group

Phase 2 Completed
Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡